What are the most valued startups in the remote patient monitoring market?

Last updated: 13 July 2026

In our updated market reports, you will find everything you need

The remote patient monitoring market includes virtual-care platforms, connected medical devices, clinical software and specialized monitoring technologies.

This ranking compares 96 remote patient monitoring startups using their latest reported valuation, public market capitalization, acquisition value or estimated valuation range.

We update this remote patient monitoring startup list every month to reflect new funding rounds, acquisitions and public-market movements.

A quick summary table

Metric	Value
Most valuable remote patient monitoring startup	Athelas, $7.0B
Second most valuable remote patient monitoring startup	iRhythm Technologies, $3.8B
Median remote patient monitoring startup valuation	Approximately $75M
Share of remote patient monitoring valuation captured by the top 10	Approximately 57%
Top remote patient monitoring valuation versus median	Approximately 93 times
Median remote patient monitoring valuation-to-capital-raised ratio	Approximately 2.2 times
Remote patient monitoring startups valued at $1B+	9

Top startups in the remote patient monitoring market ranked by valuation

Here is an updated table that ranks the top startups in the remote patient monitoring market based on their latest reported or estimated valuations.

#	Startup Name	What They Do	Current Valuation ($)	Valuation Confidence Level	Valuation Type	Evidence Status	Total Funding ($)	Funding Confidence Level
1	Athelas	Healthcare AI operations platform	$7.0B	Full Confidence	Announced Private Round Valuation	Observed	$276M	Partial Confidence
2	iRhythm Technologies	Wearable cardiac rhythm analytics	$3.8B	Full Confidence	Public Market Cap	Observed	$99M	Partial Confidence
3	Omada Health	Virtual chronic care programs	$1.4B	Full Confidence	Public Market Cap	Observed	$542M	Strong Confidence
4	Virta Health	Diabetes reversal virtual care	$1.1B–$1.3B	Strong Confidence	Announced Private Round Valuation	Observed	$402M	Strong Confidence
5	Biofourmis	AI-enabled remote care platform	$1.0B–$1.3B	Partial Confidence	Announced Private Round Valuation	Estimated	$461M	Strong Confidence
6	FIRE1	Heart failure monitoring implant	$800M–$1.3B	Partial Confidence	Implied Valuation from Raise	Implied	$227M	Strong Confidence
7	Cadence	Chronic care at home	$800M–$1.2B	Strong Confidence	Implied Valuation from Raise	Implied	$241M	Full Confidence
8	Huma	Digital health monitoring platform	$850M–$1.1B	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$355M	Partial Confidence
9	Twin Health	Metabolic digital twin care	$900M–$1.0B	Strong Confidence	Announced Private Round Valuation	Observed	$283M	Strong Confidence
10	Preventice Solutions	Remote cardiac monitoring services	$925M	Full Confidence	Acquisition Value	Observed	$138M	Partial Confidence
11	Oviva	Digital obesity and chronic care	$750M–$850M	Strong Confidence	Announced Private Round Valuation	Implied	$335M	Strong Confidence
12	Glooko	Diabetes data management platform	$650M–$950M	Partial Confidence	Implied Valuation from Raise	Implied	$201M	Strong Confidence
13	Biolinq	Wearable metabolic biosensors	$650M–$850M	Partial Confidence	Implied Valuation from Raise	Implied	$273M	Strong Confidence
14	Beta Bionics	Automated insulin delivery	$730M	Full Confidence	Public Market Cap	Observed	$570M	Strong Confidence
15	BioIntelliSense	Medical-grade wearable monitoring	$450M–$800M	Partial Confidence	Implied Valuation from Raise	Implied	$140M	Strong Confidence
16	Endotronix	Implantable heart-pressure monitoring	$600M	Full Confidence	Acquisition Value	Observed	$102M	Partial Confidence
17	Electronic Caregiver	AI virtual care monitoring	$350M–$650M	Low Confidence	Revenue or ARR Multiple Estimate	Estimated	$110M	Partial Confidence
18	Hello Heart	Digital cardiovascular care platform	$400M–$600M	Partial Confidence	Comparables-Based Estimate	Estimated	$138M	Strong Confidence
19	Vectorious Medical Technologies	Implantable left-atrial pressure monitoring	$497M	Full Confidence	Acquisition Value	Observed	$15M	Strong Confidence
20	InfoBionic	Cardiac remote monitoring platform	$300M–$600M	Partial Confidence	Implied Valuation from Raise	Implied	$135M	Partial Confidence
21	Doccla	Virtual ward monitoring services	$305M–$575M	Strong Confidence	Implied Valuation from Raise	Implied	$65M	Full Confidence
22	Lark Health	AI chronic disease coaching	$250M–$600M	Low Confidence	Comparables-Based Estimate	Estimated	$170M	Partial Confidence
23	Current Health	Hospital-at-home monitoring platform	$400M	Partial Confidence	Acquisition Value	Observed	$66M	Strong Confidence
24	VitalConnect	Wearable cardiac biosensor monitoring	$300M–$500M	Partial Confidence	Implied Valuation from Raise	Implied	$240M	Partial Confidence
25	Biobeat	Cuffless blood-pressure monitoring wearables	$330M–$450M	Strong Confidence	Implied Valuation from Raise	Implied	$51M	Strong Confidence
26	Sibel Health	Wireless vital-sign wearables	$260M–$490M	Strong Confidence	Implied Valuation from Raise	Implied	$72M	Strong Confidence
27	CoachCare	RPM care management software	$250M–$500M	Partial Confidence	Comparables-Based Estimate	Estimated	$60M	Partial Confidence
28	Bardy Diagnostics	Ambulatory cardiac monitoring patch	$375M	Full Confidence	Acquisition Value	Observed	$83M	Partial Confidence
29	Eko Health	AI cardiac and pulmonary diagnostics	$300M–$450M	Partial Confidence	Implied Valuation from Raise	Implied	$165M	Strong Confidence
30	AliveCor	Personal AI-enabled ECG devices	$280M–$430M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$134M	Partial Confidence
31	Sidekick Health	Digital therapeutics and patient support	$280M–$420M	Partial Confidence	Implied Valuation from Raise	Implied	$77M	Strong Confidence
32	TimeDoc Health	Virtual chronic care management	$240M–$405M	Partial Confidence	Implied Valuation from Raise	Implied	$58M	Strong Confidence
33	Podimetrics	Diabetic foot monitoring	$220M–$320M	Partial Confidence	Comparables-Based Estimate	Estimated	$72M	Partial Confidence
34	Accuhealth	Managed remote monitoring services	$210M–$310M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	Not provided	Low Confidence
35	Senseonics	Implantable glucose monitoring	$245M	Full Confidence	Public Market Cap	Observed	$289M	Partial Confidence
36	9am.health	Virtual cardiometabolic specialty care	$175M–$260M	Strong Confidence	Implied Valuation from Raise	Implied	$29M	Full Confidence
37	Glytec	Hospital insulin-management software	$180M–$240M	Strong Confidence	Implied Valuation from Raise	Implied	$56M	Partial Confidence
38	Bigfoot Biomedical	Connected insulin management systems	$140M–$220M	Low Confidence	Acquisition Value	Estimated	$149M	Partial Confidence
39	BeatO	Connected diabetes care platform	$130M–$190M	Partial Confidence	Comparables-Based Estimate	Estimated	$51M	Strong Confidence
40	Diabeloop	AI insulin delivery software	$120M–$190M	Partial Confidence	Implied Valuation from Raise	Implied	$125M	Partial Confidence
41	HealthSnap	Chronic-care remote monitoring platform	$120M–$170M	Partial Confidence	Implied Valuation from Raise	Implied	$49M	Strong Confidence
42	Casana	Smart toilet health monitoring	$95M–$145M	Partial Confidence	Comparables-Based Estimate	Estimated	$46M	Strong Confidence
43	Indigo Diabetes	Implantable continuous glucose sensing	$90M–$150M	Partial Confidence	Comparables-Based Estimate	Estimated	$53M	Full Confidence
44	Dozee	Contactless hospital patient monitoring	$80M–$115M	Partial Confidence	Comparables-Based Estimate	Estimated	$25M	Partial Confidence
45	Optimize Health	Remote care management platform	$75M–$120M	Partial Confidence	Implied Valuation from Raise	Implied	$40M	Strong Confidence
46	WearLinq	Wireless multi-lead ECG wearable	$70M–$115M	Strong Confidence	Implied Valuation from Raise	Implied	$21M	Strong Confidence
47	Sugar.fit	Digital diabetes reversal programs	$70M–$105M	Partial Confidence	Implied Valuation from Raise	Implied	$27M	Partial Confidence
48	mySugr	Mobile diabetes management application	$70M–$100M	Strong Confidence	Acquisition Value	Observed	$5M	Strong Confidence
49	Epitel	Wearable seizure EEG monitoring	$65M–$90M	Partial Confidence	Comparables-Based Estimate	Estimated	$13M	Strong Confidence
50	CarePredict	AI senior-care monitoring	$60M–$85M	Partial Confidence	Comparables-Based Estimate	Estimated	$42M	Partial Confidence
51	Limber Health	Hybrid musculoskeletal rehabilitation platform	$55M–$90M	Partial Confidence	Acquisition Value	Estimated	$16M	Strong Confidence
52	GraphWear	Needle-free glucose monitoring wearable	$55M–$90M	Low Confidence	Comparables-Based Estimate	Estimated	$25M	Strong Confidence
53	Elfie	Reward-based chronic-care application	$60M–$80M	Strong Confidence	Implied Valuation from Raise	Implied	$12M	Strong Confidence
54	Medical Informatics Corp	ICU analytics and virtual care	$55M–$80M	Low Confidence	Implied Valuation from Raise	Implied	$45M	Partial Confidence
55	100Plus	Medicare remote patient monitoring	$50M–$75M	Low Confidence	Acquisition Value	Estimated	$39M	Partial Confidence
56	Siren Care	Temperature-sensing diabetic socks	$50M–$75M	Strong Confidence	Implied Valuation from Raise	Implied	$25M	Strong Confidence
57	Murj	Cardiac device management software	$45M–$75M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$14M	Strong Confidence
58	Implicity	AI cardiac monitoring software	$45M–$70M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$28M	Strong Confidence
59	Nutromics	Continuous molecular monitoring patch	$45M–$70M	Partial Confidence	Comparables-Based Estimate	Estimated	$40M	Strong Confidence
60	Sweetch	AI chronic-care engagement platform	$40M–$70M	Low Confidence	Comparables-Based Estimate	Estimated	$24M	Partial Confidence
61	Validic	Connected-health data infrastructure	$40M–$65M	Low Confidence	Acquisition Value	Estimated	$32M	Strong Confidence
62	Vector Remote Care	Cardiac-device remote monitoring services	$40M–$65M	Low Confidence	Comparables-Based Estimate	Estimated	$13M	Full Confidence
63	Neteera	Contactless radar vital monitoring	$40M–$60M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$28M	Full Confidence
64	DarioHealth	Digital chronic-condition management	$46M	Full Confidence	Public Market Cap	Observed	$269M	Partial Confidence
65	Assure Health	Technology-enabled chronic disease management	$30M–$50M	Low Confidence	Comparables-Based Estimate	Estimated	$11M	Partial Confidence
66	CareMate	Wearable senior wellness monitoring	$25M–$45M	Low Confidence	Proxy-Based Estimate	Estimated	Not provided	Low Confidence
67	RhythmScience	Remote cardiac-device data management	$25M–$40M	Low Confidence	Revenue or ARR Multiple Estimate	Estimated	Not provided	Low Confidence
68	MayaMD	AI patient engagement assistant	$24M–$40M	Low Confidence	Comparables-Based Estimate	Estimated	$9M	Low Confidence
69	Ventricle Health	Virtual heart-failure specialty care	$24M–$38M	Partial Confidence	Implied Valuation from Raise	Implied	$8M	Full Confidence
70	Novi Health	Technology-enabled chronic disease care	$20M–$40M	Partial Confidence	Implied Valuation from Raise	Estimated	$5M	Full Confidence
71	Acorai	Noninvasive heart-pressure monitoring device	$23M–$34M	Partial Confidence	Implied Valuation from Raise	Implied	$11M	Partial Confidence
72	Videra Health	AI behavioral-health video monitoring	$22M–$35M	Partial Confidence	Implied Valuation from Raise	Implied	$9M	Full Confidence
73	Cecelia Health	Clinician-led chronic disease management	$24M–$30M	Strong Confidence	Announced Private Round Valuation	Observed	$52M	Partial Confidence
74	SmartCardia	Continuous ECG and vitals monitoring	$18M–$35M	Low Confidence	Comparables-Based Estimate	Estimated	Not provided	Low Confidence
75	POPS! Diabetes Care	Smartphone blood-glucose management	$20M–$32M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$10M	Strong Confidence
76	Cardiac Insight	Wearable ECG diagnostic systems	$23M	Strong Confidence	Acquisition Value	Observed	$37M	Partial Confidence
77	Lapsi Health	Digital stethoscope biomarker platform	$17M–$28M	Partial Confidence	Comparables-Based Estimate	Estimated	$6M	Strong Confidence
78	Myia Labs	AI virtual-care coordination platform	$15M–$30M	Low Confidence	Proxy-Based Estimate	Estimated	$17M	Strong Confidence
79	Qardio	Connected cardiovascular monitoring devices	$15M–$30M	Low Confidence	Proxy-Based Estimate	Estimated	$27M	Partial Confidence
80	Suvera	Virtual proactive chronic-condition care	$15M–$30M	Partial Confidence	Comparables-Based Estimate	Estimated	$5M	Full Confidence
81	BioT	Medical-device cloud infrastructure	$12M–$20M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$7M	Partial Confidence
82	Noah Labs	AI heart-failure telemonitoring	$12M–$20M	Partial Confidence	Implied Valuation from Raise	Implied	$3M	Partial Confidence
83	Tidepool	Open-source diabetes data platform	$14M–$18M	Partial Confidence	Proxy-Based Estimate	Estimated	Not provided	Low Confidence
84	HealthBeats	Remote vital-sign monitoring platform	$11M–$20M	Low Confidence	Comparables-Based Estimate	Estimated	$3M	Full Confidence
85	Fitterfly	Digital metabolic health therapeutics	$10M–$20M	Partial Confidence	Acquisition Value	Estimated	$19M	Strong Confidence
86	SmartClinix	Virtual-care operating platform	$8M–$20M	Low Confidence	Proxy-Based Estimate	Estimated	Not provided	Low Confidence
87	Oxitone Medical	Wrist-based continuous pulse oximetry	$9M–$17M	Low Confidence	Comparables-Based Estimate	Estimated	$3M	Strong Confidence
88	CARI Health	Wearable medication-level monitoring	$8M–$16M	Low Confidence	Proxy-Based Estimate	Estimated	$3M	Strong Confidence
89	Hop Technologies	AI-powered digital biomarker platform	$8M–$15M	Low Confidence	Proxy-Based Estimate	Estimated	$2M	Low Confidence
90	Nanowear	Textile cardiac monitoring sensors	$6M–$12M	Low Confidence	Proxy-Based Estimate	Estimated	$2M	Partial Confidence
91	Somatix	Wearable activity and safety monitoring	$9M	Full Confidence	Acquisition Value	Observed	$23M	Partial Confidence
92	Habitual	Type 2 diabetes reversal	$6M–$10M	Strong Confidence	Implied Valuation from Raise	Implied	$4M	Strong Confidence
93	PharmD Live	Pharmacist-led virtual chronic care	$5M–$10M	Low Confidence	Revenue or ARR Multiple Estimate	Estimated	$1M	Partial Confidence
94	ALMA.care	Proactive continuous telehealth monitoring	$4M–$9M	Low Confidence	Proxy-Based Estimate	Estimated	Not provided	Low Confidence
95	Cloud DX	Virtual-care monitoring platform	$1M–$5M	Low Confidence	Acquisition Value	Estimated	$12M	Partial Confidence
96	NanoVation	Wearable respiratory deterioration monitoring	$1M–$4M	Low Confidence	Proxy-Based Estimate	Estimated	$6M	Strong Confidence
97	Nemaura Medical	Non-invasive glucose monitoring patches	<$1M	Strong Confidence	Public Market Cap	Observed	$2M	Low Confidence
98	Medella Health	Glucose-monitoring smart contact lenses	$0M–$1M	Low Confidence	Proxy-Based Estimate	Estimated	$1M	Strong Confidence

Key valuation trends in the remote patient monitoring market

Insights

The top 10 remote patient monitoring startups represent approximately $19.5B, or 57% of the market’s estimated $34.3B total valuation, showing a high concentration of value among scaled platforms.
Vectorious Medical Technologies reached a $497M acquisition value after raising only $15M, creating a value-to-funding multiple of roughly 33 times, the strongest substantiated outcome in the ranking.
Omada Health and Beta Bionics raised approximately $1.1B combined, but the two public companies are valued at about $2.1B, highlighting the capital intensity of chronic-care and medical-device commercialization.
Virta Health, Twin Health and Oviva have a combined midpoint valuation near $3.0B after raising roughly $1.0B, producing an aggregate valuation-to-funding multiple of about three times.
Cadence has a midpoint valuation near $1.0B, more than four times its $241M funding total, which suggests strong capital efficiency for a full-service chronic-care delivery platform.
Biobeat, Sibel Health, WearLinq and Siren Care have combined midpoint valuations near $920M against $169M of disclosed funding, showing strong investor demand for specialized clinical wearables.
Doccla has a midpoint valuation of approximately $440M after raising $65M, suggesting that virtual-ward providers can scale efficiently through recurring health-system contracts.
The remote patient monitoring startups with the strongest acquisition outcomes usually control differentiated clinical technology, proprietary patient data or a deeply embedded medical workflow.
Software-led chronic-care platforms hold the largest absolute valuations, while specialized monitoring devices and focused data products often produce the highest valuation-to-funding multiples.

A few word about our methodology

As you can see, we built a database that ranks startups in the remote patient monitoring market based on their current valuation.

Estimating remote patient monitoring startup valuations is not always straightforward. Many companies do not publicly disclose their valuation, and the available information can vary widely depending on the company and its stage.

To build this ranking, we applied a structured valuation methodology and cross-checked information across multiple reliable sources.

Whenever possible, we relied on direct disclosures. These include announced valuations from completed funding rounds, public filings for listed companies, or official acquisition prices.

When a remote patient monitoring company is publicly listed, we use its current market capitalization as the reference valuation.

If a company was acquired and no independent valuation can reasonably be estimated today, we use the acquisition price as the main reference point.

When a remote patient monitoring startup recently raised capital but the valuation was not disclosed, we estimate the implied valuation using typical dilution levels for that stage of fundraising.

In some cases, we also estimate valuations using operating metrics such as revenue, ARR, covered patients, clinical contracts or customer traction, combined with valuation multiples from comparable remote patient monitoring companies.

When direct financial data is not available, we may rely on carefully selected comparable startups and other signals such as hiring growth, investor quality, regulatory progress, reimbursement access or product traction.

All estimates follow a strict evidence hierarchy. Recent funding rounds with announced valuations carry the most weight, followed by strong operating metrics and comparable company analysis.

We also carefully evaluate the age of every data point. Recent information carries more weight, while older data is treated cautiously and adjusted conservatively when necessary.

Whenever information is uncertain or incomplete, we clearly distinguish between confirmed facts and reasonable inferences.

Because valuation data is not always fully public, each remote patient monitoring startup in the ranking is assigned a confidence level based on the reliability, recency and consistency of the available evidence.

Full confidence means the valuation is supported by strong and recent evidence. Strong confidence means the estimate is well supported but includes minor inference. Partial confidence means the estimate relies more heavily on indirect signals. Low confidence means available information is limited or inconsistent.

When confidence is lower, we take a more conservative approach by widening the valuation range. This helps reflect the uncertainty and increases the probability that the true valuation falls within the estimated range.

In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.

If you want the full detail on a specific valuation estimate, feel free to contact us and we will gladly explain.

Finally, know that we update the dataset once per month, so come back here if you need fresh information.

Related blog posts

- The main fundraising trends in the remote patient monitoring market

- The startups that have raised the most funding in the remote patient monitoring market

- How healthy is startup funding in the remote patient monitoring market right now?

- All the funding deals in the remote patient monitoring market

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.

Back to blog